Kohei Kobatake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kohei Kobatake has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Nobuyuki Hinata
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
34 shared publications Keisuke Hieda
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
28 shared publications- Hiroyuki Kitano
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
24 shared publications - Keisuke Goto
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
23 shared publications Akihiro Goriki
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
21 shared publications- Yohei Sekino
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
21 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 1099
Video-based analysis of camera–instrument distance dynamics and operative efficiency in expert and novice robot-assisted partial nephrectomy
- 13 October 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 1099
Open AccessVideo-based analysis of camera–instrument distance dynamics and operative efficiency in expert and novice robot-assisted partial nephrectomy
- Open Access
- 20 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Photodynamic diagnosis-assisted ureteroscopy for upper tract urothelial carcinoma achieves improved diagnostic performance using quantitative color image analysis
- 20 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPhotodynamic diagnosis-assisted ureteroscopy for upper tract urothelial carcinoma achieves improved diagnostic performance using quantitative color image analysis
- Open Access
- 8 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1)
Impact of surgical start time on clinical outcomes in urologic surgery: a single-center study of major oncologic surgeries and adrenalectomy
- 8 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1)
Open AccessImpact of surgical start time on clinical outcomes in urologic surgery: a single-center study of major oncologic surgeries and adrenalectomy
- Open Access
- 5 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8)
RIOK2 Promotes Clear Cell Renal Cell Carcinoma Progression Through Cell Cycle Regulation
Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer and is frequently associated with poor clinical outcomes. Ribosome biogenesis, which is upregulated in many malignancies, plays a key role in tumor proliferation. Right open reading frame kinase 2 (RIOK2) is an atypical kinase essential for 40S ribosomal subunit maturation, but its role in ccRCC remains unexplored. We investigated the clinical and biological significance of RIOK2 in ccRCC. Immunohistochemical analysis of 166 ccRCC specimens revealed that high RIOK2 expression was significantly associated with advanced pathological stage, higher tumor grade, and shorter cancer‐specific and progression‐free survival. Public datasets confirmed the elevated RIOK2 mRNA expression in ccRCC, and its association with poor prognosis. Functional studies demonstrated that RIOK2 knockdown suppressed the proliferation, invasion, and migration of ccRCC cells. RNA sequencing, followed by gene set enrichment analysis, revealed that RIOK2 knockdown led to the downregulation of cell cycle‐related pathways, including E2F targets. Analyses of public datasets further highlighted suppression of the G2/M checkpoint. Flow cytometry revealed G1 cell cycle arrest accompanied by reduced CDK2 protein expression in RIOK2‐knockdown cells. Furthermore, the small‐molecule RIOK2 inhibitor, NSC139021, suppressed ccRCC cell proliferation in a dose‐dependent manner, with reduced efficiency in RIOK2‐knockdown cells. Collectively, these findings identify RIOK2 as a clinically relevant factor associated with aggressive disease behavior and cell‐cycle regulation in ccRCC.
- 5 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8)
Open AccessRIOK2 Promotes Clear Cell Renal Cell Carcinoma Progression Through Cell Cycle Regulation
Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer and is frequently associated with poor clinical outcomes. Ribosome biogenesis, which is upregulated in many malignancies, plays a key role in tumor proliferation. Right open reading frame kinase 2 (RIOK2) is an atypical kinase essential for 40S ribosomal subunit maturation, but its role in ccRCC remains unexplored. We investigated the clinical and biological significance of RIOK2 in ccRCC. Immunohistochemical analysis of 166 ccRCC specimens revealed that high RIOK2 expression was significantly associated with advanced pathological stage, higher tumor grade, and shorter cancer‐specific and progression‐free survival. Public datasets confirmed the elevated RIOK2 mRNA expression in ccRCC, and its association with poor prognosis. Functional studies demonstrated that RIOK2 knockdown suppressed the proliferation, invasion, and migration of ccRCC cells. RNA sequencing, followed by gene set enrichment analysis, revealed that RIOK2 knockdown led to the downregulation of cell cycle‐related pathways, including E2F targets. Analyses of public datasets further highlighted suppression of the G2/M checkpoint. Flow cytometry revealed G1 cell cycle arrest accompanied by reduced CDK2 protein expression in RIOK2‐knockdown cells. Furthermore, the small‐molecule RIOK2 inhibitor, NSC139021, suppressed ccRCC cell proliferation in a dose‐dependent manner, with reduced efficiency in RIOK2‐knockdown cells. Collectively, these findings identify RIOK2 as a clinically relevant factor associated with aggressive disease behavior and cell‐cycle regulation in ccRCC.
- Open Access
- 23 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70579
External Validation of Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma in a Japanese Cohort: Evaluation of Predictive Performance
Objectives: To characterize contemporary postoperative outcomes and risk stratification in a large Japanese real‐world cohort of patients with clinically nonmetastatic clear cell renal cell carcinoma (ccRCC), and to externally validate commonly used prognostic models. Methods: We retrospectively analyzed 1677 Japanese patients with clinically nonmetastatic ccRCC who underwent radical or partial nephrectomy between 2010 and 2025. Disease‐free survival (DFS) and overall survival (OS) were evaluated. The Leibovich score, SSIGN score, AUA risk groups, and GRANT score were externally validated. Model discrimination was assessed using Harrell's C‐index. Results: During a median follow‐up of 36 months, 160 patients (9.5%) experienced recurrence and 115 (6.9%) died, including 28 renal cancer‐specific deaths. The 3‐, 5‐, and 10‐year DFS rates were 91.2%, 87.6%, and 75.9%, respectively; corresponding OS rates were 95.0%, 91.1%, and 80.9%. Pathological T stage, WHO/ISUP grade, and lymphovascular invasion (LVI) were independently associated with DFS, whereas age, ASA physical status, and LVI were independently associated with OS. All four models significantly stratified DFS and OS. For DFS, the Leibovich score showed favorable discrimination, with a C‐index of 0.785 as a continuous score and 0.769 as a risk‐group model. In a post hoc exploratory analysis, adding LVI to the Leibovich score slightly increased the C‐index for DFS, but the improvement was not statistically significant. Conclusions: Established prognostic models consistently stratified recurrence risk in Japanese patients with clinically nonmetastatic ccRCC. The Leibovich score may serve as a useful reference for postoperative risk assessment, whereas the added value of LVI requires further validation.
- 23 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70579
Open AccessExternal Validation of Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma in a Japanese Cohort: Evaluation of Predictive Performance
Objectives: To characterize contemporary postoperative outcomes and risk stratification in a large Japanese real‐world cohort of patients with clinically nonmetastatic clear cell renal cell carcinoma (ccRCC), and to externally validate commonly used prognostic models. Methods: We retrospectively analyzed 1677 Japanese patients with clinically nonmetastatic ccRCC who underwent radical or partial nephrectomy between 2010 and 2025. Disease‐free survival (DFS) and overall survival (OS) were evaluated. The Leibovich score, SSIGN score, AUA risk groups, and GRANT score were externally validated. Model discrimination was assessed using Harrell's C‐index. Results: During a median follow‐up of 36 months, 160 patients (9.5%) experienced recurrence and 115 (6.9%) died, including 28 renal cancer‐specific deaths. The 3‐, 5‐, and 10‐year DFS rates were 91.2%, 87.6%, and 75.9%, respectively; corresponding OS rates were 95.0%, 91.1%, and 80.9%. Pathological T stage, WHO/ISUP grade, and lymphovascular invasion (LVI) were independently associated with DFS, whereas age, ASA physical status, and LVI were independently associated with OS. All four models significantly stratified DFS and OS. For DFS, the Leibovich score showed favorable discrimination, with a C‐index of 0.785 as a continuous score and 0.769 as a risk‐group model. In a post hoc exploratory analysis, adding LVI to the Leibovich score slightly increased the C‐index for DFS, but the improvement was not statistically significant. Conclusions: Established prognostic models consistently stratified recurrence risk in Japanese patients with clinically nonmetastatic ccRCC. The Leibovich score may serve as a useful reference for postoperative risk assessment, whereas the added value of LVI requires further validation.
- Open Access
- 30 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.
- 30 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessClinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.
- Open Access
- 8 June 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70538
Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/ DD ) and Pure Urothelial Carcinoma Using a Large‐Scale Japanese Genomic Panel Dataset
Objectives: Urothelial carcinoma (UC) is a common malignancy; however, UC subtypes/divergent differentiation (S/DD) accounts for only 10%–20% of overall cases. S/DD's aggressive biological behavior significantly affects its prognosis and therapeutic decision‐making; thus, elucidating its genomic landscape within UC is important. This retrospective observational study aimed to evaluate and compare the molecular characteristics of S/DD and pure urothelial carcinoma (PUC). Methods: Comprehensive cancer genomic profiling data were obtained from the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) and the MSK2022 dataset. The association between S/DD and clinicopathological features was evaluated in an independent Hiroshima University cohort. Results: Across both C‐CAT and MSK2022 datasets, TP53 and RB1 mutations were more prevalent in S/DD, whereas KDM6A , ARID1A , and FGFR3 mutations were more common in PUC. High‐frequency copy number alterations included MYC and RB1 in S/DD, and CDKN2A , CDKN2B , CCND1 , FGF19 , FGF4 , and FGF3 in PUC. In the Hiroshima University cohort, S/DD was associated with adverse clinicopathological features and a poor prognosis. Immunohistochemistry demonstrated a positive correlation of S/DD with PD‐L1, EGFR, and p53 expression in upper tract UC tissues, and an inverse correlation with FGFR3, GATA3, Nectin4, and TROP2 expression. Conclusions: Using a large‐scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin‐4 expression and basal‐like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
- 8 June 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70538
Open AccessComprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/ DD ) and Pure Urothelial Carcinoma Using a Large‐Scale Japanese Genomic Panel Dataset
Objectives: Urothelial carcinoma (UC) is a common malignancy; however, UC subtypes/divergent differentiation (S/DD) accounts for only 10%–20% of overall cases. S/DD's aggressive biological behavior significantly affects its prognosis and therapeutic decision‐making; thus, elucidating its genomic landscape within UC is important. This retrospective observational study aimed to evaluate and compare the molecular characteristics of S/DD and pure urothelial carcinoma (PUC). Methods: Comprehensive cancer genomic profiling data were obtained from the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) and the MSK2022 dataset. The association between S/DD and clinicopathological features was evaluated in an independent Hiroshima University cohort. Results: Across both C‐CAT and MSK2022 datasets, TP53 and RB1 mutations were more prevalent in S/DD, whereas KDM6A , ARID1A , and FGFR3 mutations were more common in PUC. High‐frequency copy number alterations included MYC and RB1 in S/DD, and CDKN2A , CDKN2B , CCND1 , FGF19 , FGF4 , and FGF3 in PUC. In the Hiroshima University cohort, S/DD was associated with adverse clinicopathological features and a poor prognosis. Immunohistochemistry demonstrated a positive correlation of S/DD with PD‐L1, EGFR, and p53 expression in upper tract UC tissues, and an inverse correlation with FGFR3, GATA3, Nectin4, and TROP2 expression. Conclusions: Using a large‐scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin‐4 expression and basal‐like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
- Open Access
Bone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma
Background: Tumor–stroma interactions play a critical role in renal cell carcinoma (RCC) progression. Cancer-associated fibroblasts (CAFs) are considered key components of the tumor microenvironment; however, their origin remains controversial. This study aimed to determine whether bone marrow-derived mesenchymal stem cells (MSCs) contribute to CAF-like stromal changes and RCC progression. Methods: An orthotopic xenograft mouse model was established using luciferase- and GFP-labeled Caki-1 cells. MSCs labeled with PKH26 were administered intravenously. Tumor growth was evaluated using an in vivo imaging system and tumor volume measurements. Immunohistochemical analyses were performed to assess MSC localization and α-smooth muscle actin (α-SMA) expression. In vitro proliferation and migration assays were conducted using direct and indirect co-culture systems. Results: The intravenous administration of MSCs significantly increased tumor growth and bioluminescence intensity in an orthotopic model. The tumor volumes were significantly larger in the MSC-treated versus control group. An immunofluorescence analysis demonstrated partial co-localization of PKH26-labeled MSCs with α-SMA-positive fibroblast-like cells, suggesting acquisition of CAF-like features. Direct co-culture with MSCs significantly enhanced RCC cell proliferation and migration in vitro, whereas culturing in conditioned medium alone did not produce similar effects. Conclusions: Exogenously administered bone marrow-derived MSCs may be recruited into RCC tissues and acquire CAF-like features through interactions with tumor cells. These findings suggest that stromal–tumor cell interactions within the tumor microenvironment may contribute to RCC progression and represent a potential therapeutic target.
Open AccessBone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma
Background: Tumor–stroma interactions play a critical role in renal cell carcinoma (RCC) progression. Cancer-associated fibroblasts (CAFs) are considered key components of the tumor microenvironment; however, their origin remains controversial. This study aimed to determine whether bone marrow-derived mesenchymal stem cells (MSCs) contribute to CAF-like stromal changes and RCC progression. Methods: An orthotopic xenograft mouse model was established using luciferase- and GFP-labeled Caki-1 cells. MSCs labeled with PKH26 were administered intravenously. Tumor growth was evaluated using an in vivo imaging system and tumor volume measurements. Immunohistochemical analyses were performed to assess MSC localization and α-smooth muscle actin (α-SMA) expression. In vitro proliferation and migration assays were conducted using direct and indirect co-culture systems. Results: The intravenous administration of MSCs significantly increased tumor growth and bioluminescence intensity in an orthotopic model. The tumor volumes were significantly larger in the MSC-treated versus control group. An immunofluorescence analysis demonstrated partial co-localization of PKH26-labeled MSCs with α-SMA-positive fibroblast-like cells, suggesting acquisition of CAF-like features. Direct co-culture with MSCs significantly enhanced RCC cell proliferation and migration in vitro, whereas culturing in conditioned medium alone did not produce similar effects. Conclusions: Exogenously administered bone marrow-derived MSCs may be recruited into RCC tissues and acquire CAF-like features through interactions with tumor cells. These findings suggest that stromal–tumor cell interactions within the tumor microenvironment may contribute to RCC progression and represent a potential therapeutic target.
- Open Access
- 20 May 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (5) , e70507
Prognostic Significance of Pretreatment Blood‐Based Biomarkers in Penile Cancer: A Multicenter Retrospective Study in Japan
Objectives: Penile cancer is a rare malignancy, and multicenter data evaluating prognostic biomarkers in the Japanese population are limited. This study aimed to assess the prognostic significance of pretreatment blood‐based biomarkers in patients with penile cancer. Methods: We conducted a multicenter retrospective cohort study including 111 patients with penile cancer treated between January 2005 and December 2023 at ten institutions participating in the West Japan Uro‐oncology Collaboration Group. Cancer–specific survival (CSS) was analyzed using the Kaplan–Meier method and Cox proportional hazards model. Receiver operating characteristic analyses were performed to determine optimal cutoff values for the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and squamous cell carcinoma antigen (SCC‐Ag). A composite biomarker score was calculated based on the number of elevated biomarkers. Results: The 5‐year overall survival and CSS rates were 71.1% and 77.4%, respectively. In univariate analyses, elevated PLR, elevated SCC‐Ag, and higher composite biomarker scores were significantly associated with poorer CSS. In multivariate analysis, advanced clinical nodal status (≥ cN2) and distant metastasis (cM1) remained independent predictors of CSS, whereas blood‐based biomarkers did not retain independent prognostic significance after adjustment for established clinicopathological factors. Kaplan–Meier analyses demonstrated significantly worse CSS in patients with high PLR, high SCC‐Ag levels, and higher composite biomarker scores. Conclusions: Pretreatment blood‐based biomarkers, particularly PLR and SCC‐Ag, are associated with prognosis in penile cancer. Although they did not retain independent prognostic factors after adjustment, these biomarkers may provide complementary prognostic information and help identify high‐risk patients in clinical practice.
- 20 May 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (5) , e70507
Open AccessPrognostic Significance of Pretreatment Blood‐Based Biomarkers in Penile Cancer: A Multicenter Retrospective Study in Japan
Objectives: Penile cancer is a rare malignancy, and multicenter data evaluating prognostic biomarkers in the Japanese population are limited. This study aimed to assess the prognostic significance of pretreatment blood‐based biomarkers in patients with penile cancer. Methods: We conducted a multicenter retrospective cohort study including 111 patients with penile cancer treated between January 2005 and December 2023 at ten institutions participating in the West Japan Uro‐oncology Collaboration Group. Cancer–specific survival (CSS) was analyzed using the Kaplan–Meier method and Cox proportional hazards model. Receiver operating characteristic analyses were performed to determine optimal cutoff values for the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and squamous cell carcinoma antigen (SCC‐Ag). A composite biomarker score was calculated based on the number of elevated biomarkers. Results: The 5‐year overall survival and CSS rates were 71.1% and 77.4%, respectively. In univariate analyses, elevated PLR, elevated SCC‐Ag, and higher composite biomarker scores were significantly associated with poorer CSS. In multivariate analysis, advanced clinical nodal status (≥ cN2) and distant metastasis (cM1) remained independent predictors of CSS, whereas blood‐based biomarkers did not retain independent prognostic significance after adjustment for established clinicopathological factors. Kaplan–Meier analyses demonstrated significantly worse CSS in patients with high PLR, high SCC‐Ag levels, and higher composite biomarker scores. Conclusions: Pretreatment blood‐based biomarkers, particularly PLR and SCC‐Ag, are associated with prognosis in penile cancer. Although they did not retain independent prognostic factors after adjustment, these biomarkers may provide complementary prognostic information and help identify high‐risk patients in clinical practice.
- Open Access
- 22 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1053-1060
Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
Background: Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC). The Nadir ARSI‐Derived Integrative Response (NADIR) model was recently developed using Phase III trial data to predict the probability of achieving a favorable early PSA response. However, its performance in real‐world clinical settings remains unclear. Methods: We retrospectively reviewed 196 patients with mCSPC who received first‐line ARSI therapy at Hiroshima University Hospital and affiliated institutions between 2018 and 2025; 186 had complete data required to calculate the NADIR score. An early favorable PSA response was defined as a decline in PSA to ≤ 0.2 ng/mL within 6 months of treatment initiation. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and calibration was evaluated using calibration plots. Patients were stratified into tertiles based on the NADIR score, and time‐to‐event outcomes, including overall survival (OS) and time to castration‐resistant prostate cancer (CRPC), were analyzed using the Kaplan–Meier method. Results: The proportion of patients with an early favorable PSA response decreased stepwise across the upper, middle, and lower tertiles (61.3%, 33.8%, and 17.7%, respectively; Cochran–Armitage trend test, p < 0.01). The NADIR model demonstrated acceptable discrimination for predicting an early favorable PSA response, with an AUC of 0.74 (95% confidence interval [CI] 0.66–0.81). Agreement between predicted probabilities and observed outcomes was maintained across NADIR‐defined risk groups. In a univariable analysis treating the NADIR score as a continuous variable, higher NADIR scores were strongly associated with an early favorable PSA response (odds ratio per 10% increase, 1.74; 95% CI 1.36–2.23; p < 0.001). CRPC‐free survival differed significantly across NADIR‐defined tertiles, whereas OS did not differ significantly. Conclusions: In this real‐world cohort, the NADIR model retained acceptable predictive performance, suggesting applicability in routine clinical practice and potential utility in individualized pretreatment clinical management.
- 22 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1053-1060
Open AccessImpact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
Background: Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC). The Nadir ARSI‐Derived Integrative Response (NADIR) model was recently developed using Phase III trial data to predict the probability of achieving a favorable early PSA response. However, its performance in real‐world clinical settings remains unclear. Methods: We retrospectively reviewed 196 patients with mCSPC who received first‐line ARSI therapy at Hiroshima University Hospital and affiliated institutions between 2018 and 2025; 186 had complete data required to calculate the NADIR score. An early favorable PSA response was defined as a decline in PSA to ≤ 0.2 ng/mL within 6 months of treatment initiation. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and calibration was evaluated using calibration plots. Patients were stratified into tertiles based on the NADIR score, and time‐to‐event outcomes, including overall survival (OS) and time to castration‐resistant prostate cancer (CRPC), were analyzed using the Kaplan–Meier method. Results: The proportion of patients with an early favorable PSA response decreased stepwise across the upper, middle, and lower tertiles (61.3%, 33.8%, and 17.7%, respectively; Cochran–Armitage trend test, p < 0.01). The NADIR model demonstrated acceptable discrimination for predicting an early favorable PSA response, with an AUC of 0.74 (95% confidence interval [CI] 0.66–0.81). Agreement between predicted probabilities and observed outcomes was maintained across NADIR‐defined risk groups. In a univariable analysis treating the NADIR score as a continuous variable, higher NADIR scores were strongly associated with an early favorable PSA response (odds ratio per 10% increase, 1.74; 95% CI 1.36–2.23; p < 0.001). CRPC‐free survival differed significantly across NADIR‐defined tertiles, whereas OS did not differ significantly. Conclusions: In this real‐world cohort, the NADIR model retained acceptable predictive performance, suggesting applicability in routine clinical practice and potential utility in individualized pretreatment clinical management.